Suntrust Banks’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Suntrust Banks’s Portfolio EGRX Stock Details EGRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	$1.04M	Buy	18,375 +133	+0.7%	+$7.48K	0.01%	739
2019 Q2	$1.01M	Hold	18,242	–	–	0.01%	769
2019 Q1	$921K	Buy	+18,242	New	+$812K	﹤0.01%	790
2018 Q4	–	Sell	-4,806	Closed	-$333K	–	1344
2018 Q3	$333K	Buy	4,806 +187	+4%	+$14.2K	﹤0.01%	1039
2018 Q2	$349K	Buy	+4,619	New	+$291K	﹤0.01%	1050

Other funds holding EGRX

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PWAM

Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return

HEC

Hudson Executive Capital New York $151M AUM 60.14% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Suntrust Banks's EGRX Position: Q3 2019 in Review

Suntrust Banks increased its Eagle Pharmaceuticals, Inc. (EGRX) stake by 0.73% in Q3 2019, buying an estimated $7.48K and bringing the position to 18,375 shares worth $1.04M. The position accounts for 0.01% of the portfolio, ranked #739.

Suntrust Banks first reported a position in EGRX in Q2 2018 and has held it in 5 quarters since. 183 funds tracked by Wall St. Rank hold EGRX as of Q3 2019.

Suntrust Banks held 18,375 shares of Eagle Pharmaceuticals, Inc. worth $1.04M as of Q3 2019.
Suntrust Banks bought 133 Eagle Pharmaceuticals, Inc. shares in Q3 2019, an estimated $7.48K.
Eagle Pharmaceuticals, Inc. made up 0.01% of Suntrust Banks's portfolio in Q3 2019, its #739 holding.
Suntrust Banks first reported a position in Eagle Pharmaceuticals, Inc. in Q2 2018 and has held it in 5 quarters since.
183 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q3 2019.

Based on Suntrust Banks's 13F filing for Q3 2019, filed 12 Nov 2019.